Srikripa Devarakonda
Stock Analyst at Truist Securities
(0.75)
# 2189
Out of 5,329 analysts
68
Total ratings
34.69%
Success rate
0.19%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceut... | Maintains: Buy | 975 940 | 588.6 | 59.7% | 7 | Apr 30, 2025 | |
BIIB Biogen | Maintains: Buy | 210 199 | 121 | 64.46% | 4 | Apr 29, 2025 | |
KROS Keros Therapeutics | Maintains: Buy | 43 25 | 14.58 | 71.47% | 5 | Apr 9, 2025 | |
INCY Incyte | Maintains: Hold | 74 72 | 62.09 | 15.96% | 9 | Mar 18, 2025 | |
PTGX Protagonist Therapeu... | Maintains: Strong Buy | 60 76 | 45.16 | 68.29% | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 1029 1038 | 794.79 | 30.6% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 211 217 | 193.41 | 12.2% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 32 | 23.91 | 33.84% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 33 50 | 16.71 | 199.22% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 36 45 | 32.84 | 37.03% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 54 53 | 34.63 | 53.05% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 54 54 | 2.03 | 2560.1% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 15 | 7.46 | 101.07% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 36 | 11.2 | 221.43% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 86 70 | 43.03 | 62.68% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 80 60 | 1.09 | 5404.59% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 38 | n/a | n/a | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 50 34 | n/a | n/a | 2 | Jun 3, 2021 |